Skip to main content

Ironwood Pharmaceuti(IRWD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.36
Day High3.65
Open:3.57
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Ironwood Pharmaceuti

Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD)
Tipranks
Ironwood Pharma Maintains Revolving Credit Facility to 2028
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Delcath Systems (DCTH), Viridian Therapeutics (VRDN)
Motley Fool
Ironwood (IRWD) Q4 2025 Earnings Call Transcript
Tipranks
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ironwood Pharma (IRWD)
MarketBeat
3 Stocks Trading Near $5 With Massive Earnings Upside
MarketBeat.com
Zacks Investment Research
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
MarketBeat
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating
MarketBeat.com
Zacks Investment Research
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Zacks Investment Research
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
Tipranks
Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M
Tipranks
Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M
Tipranks
Ironwood Pharma Resolves Ferring Dispute, Amends License Terms
Tipranks
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)
Tipranks
Ironwood Pharma’s LINZESS® Price Set by HHS
Tipranks
Ironwood Pharma (IRWD) Gets a Hold from Wells Fargo
Tipranks
Ironwood Pharmaceuticals Reports Strong Q3 2025 Earnings
Tipranks
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Aziyo Biologics (ELUT) and Ironwood Pharma (IRWD)
Business Wire
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Tipranks
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Ironwood Pharma (IRWD)
Tipranks
Craig-Hallum Sticks to Its Hold Rating for Ironwood Pharma (IRWD)
Zacks Investment Research
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Zacks Investment Research
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Tipranks
Ironwood Pharma Board Member Resigns for New Role
Tipranks
Ironwood Pharma Regains Nasdaq Compliance
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 89bio (ETNB), Relay Therapeutics (RLAY) and Ironwood Pharma (IRWD)
Tipranks
Craig-Hallum Remains a Hold on Ironwood Pharma (IRWD)
Motley Fool
Ironwood (IRWD) Q2 EPS Jumps 600%
Business Wire
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
Tipranks
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), LENZ Therapeutics (LENZ) and Ironwood Pharma (IRWD)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Codexis (CDXS) and Ironwood Pharma (IRWD)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), AbbVie (ABBV) and Molecular Partners (MOLN)

Profile

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.